NCT00311038 is a Phase 2 clinical trial of ONO-1101 in Coronary Artery Disease, sponsored by Ono Pharmaceutical Co., Ltd..

Who is sponsoring NCT00311038?

NCT00311038 is sponsored by Ono Pharmaceutical Co., Ltd..

What drugs are being tested in NCT00311038?

Interventions in NCT00311038: ONO-1101.

What condition does NCT00311038 study?

NCT00311038 studies Coronary Artery Disease.

Is NCT00311038 still recruiting?

NCT00311038 is currently completed. Last updated 12 June 2012.

Last reviewed 2012-06-12 · How we verify

NCT00311038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice Computed Tomography (CT) Due to Suspected Coronary Artery Disease

Completed Phase 2 Last updated 12 June 2012

What this trial tests

Phase 2 trial testing ONO-1101 in Coronary Artery Disease in 90 participants. Completed.

Timeline

1 April 2006

Quick facts

Lead sponsor	Ono Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	90
Start date	1 April 2006
Sites	3 locations across Japan

Drugs / interventions tested

ONO-1101 — full drug profile →

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Ono Pharmaceutical Co., Ltd.

Who can join

Adults 20 to 74, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

heart rate
image quality
safety

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for multi-slice CT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dose-finding study of landiolol hydrochloride: a short-acting β1-blocker for controlling heart rate during coronary computed-tomography angiography in Japan.
Hirano M, Hara K, Ikari Y, Jinzaki M, et al · · 2013 · cited 6× · PMID 24062147 · DOI 10.1007/s12325-013-0053-0

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Ono Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07169708 — A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable · not yet recruiting
NCT06936943 — ONO-4538 Study in Patients With Richter's Transformation · Phase 2 · recruiting
NCT06948448 — A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 an · Phase 2 · recruiting
NCT07198087 — A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impa · Phase 1 · active not recruiting
NCT06803823 — A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00311038 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ono Pharmaceutical Co., Ltd.
Last refreshed: 12 June 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00311038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing